NewAmsterdam Pharma Company NV (NAMS) reported disappointing financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) came in at $-0.61, missing Wall Street's consensus estimate of $-0.40 by $0.21. Revenue remained at $0.0B, aligning with expectations but not providing the needed boost to reassure investors.
The announcement highlights ongoing challenges for the company, which is focused on developing transformative oral therapies for major cardiometabolic diseases. NewAmsterdam Pharma is currently investigating obicetrapib, a low-dose, once-daily cholesteryl ester transfer protein (CETP) inhibitor aimed at lowering low-density lipoprotein cholesterol (LDL-C) for high-risk cardiovascular disease patients.
The company will host its earnings conference call at BMO to discuss these results further and provide additional commentary on its business performance. Investors are encouraged to review the full earnings release and listen to management's insights for a complete context on the quarter's performance and future outlook.
Looking ahead, NewAmsterdam Pharma's upcoming earnings are scheduled for May 5, 2026, with an EPS estimate of $-0.4544, and another report on August 3, 2026, with an EPS estimate of $-0.4983. As of November 8, 2025, the company has a market cap of $4,168.25 and a trailing twelve months (TTM) EPS of $-1.59.